Form 4: Twist Bioscience SVP Sells Shares for Tax Obligations

Twist Bioscience SVP of Human Resources, Paula Green, sold 1,465 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Paula Green, SVP of Human Resources at Twist Bioscience Corp (TWST), reported a transaction involving the company's common stock.
• On February 23, 2026, Green disposed of 1,465 shares of common stock.
• The shares were sold at a price of $46.7098 per share.
• This sale was explicitly stated as a 'sell to cover' transaction, mandated by the issuer's equity incentive plans to satisfy tax withholding obligations associated with the vesting of Restricted Stock Units (RSUs).
• The transaction does not represent a discretionary trade by the reporting person.
• Following this transaction, Paula Green beneficially owns 125,336 shares of Twist Bioscience common stock.
• The reported beneficial ownership includes shares acquired under the Issuer's Employee Stock Purchase Plan, which were exempt under Rule 16b-3(d) and Rule 16b-3(c).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While it involves a sale of shares, it is explicitly a non-discretionary 'sell to cover' transaction for tax purposes, rather than a voluntary divestment, which typically does not signal a change in management's outlook.

Positives

• The transaction was a non-discretionary 'sell to cover' sale, indicating it was not a voluntary decision by the insider to reduce their stake due to a lack of confidence in the company.
• The insider continues to hold a substantial number of shares (125,336), demonstrating continued alignment with shareholder interests.

Negatives

• No inherent negatives are identified as the sale was non-discretionary and for tax purposes.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The sale of 1,465 shares represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units.
• These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a 'sell to cover' transaction and do not represent discretionary trades by the Reporting Person.

Industry Context

StockSavvy.ai notes that 'sell to cover' transactions are a standard and routine practice for executives and employees receiving equity compensation, such as Restricted Stock Units (RSUs), to meet tax liabilities upon vesting. This type of transaction is common across all industries where equity compensation is prevalent.

Comparison to Industry Standards

• This 'sell to cover' transaction aligns with common industry practices for managing tax obligations arising from equity compensation. Companies like Moderna (MRNA) and NVIDIA (NVDA) frequently see similar Form 4 filings from their executives for tax-related share disposals, which are generally not interpreted as a change in management's confidence in the company's prospects.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary transaction for tax purposes and does not signal a change in management's confidence.
• Employees: The transaction highlights the company's equity incentive plans and how tax obligations are managed for RSU vesting.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary 'sell to cover' transaction by an insider to satisfy tax obligations. It does not provide new information that would fundamentally alter the investment thesis for Twist Bioscience. Therefore, a seasoned investor or institution would likely maintain their current position, resulting in a 'hold' recommendation.

Keywords

Twist Bioscience, TWST, Form 4, Insider Transaction, Stock Sale, Tax Withholding, Restricted Stock Units, Equity Compensation